910 related articles for article (PubMed ID: 22080568)
21. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.
Sartori G; Cavazza A; Bertolini F; Longo L; Marchioni A; Costantini M; Barbieri F; Migaldi M; Rossi G
Am J Clin Pathol; 2008 Feb; 129(2):202-10. PubMed ID: 18208799
[TBL] [Abstract][Full Text] [Related]
22. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
[TBL] [Abstract][Full Text] [Related]
23. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
24. Cathepsin D as a potential prognostic marker for lung adenocarcinoma.
Mimae T; Tsuta K; Maeshima AM; Okada M; Asamura H; Kondo T; Tsuda H
Pathol Res Pract; 2012 Sep; 208(9):534-40. PubMed ID: 22824147
[TBL] [Abstract][Full Text] [Related]
25. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.
Brachtel EF; Iafrate AJ; Mark EJ; Deshpande V
Diagn Cytopathol; 2007 May; 35(5):257-62. PubMed ID: 17427221
[TBL] [Abstract][Full Text] [Related]
26. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.
Sartori G; Cavazza A; Sgambato A; Marchioni A; Barbieri F; Longo L; Bavieri M; Murer B; Meschiari E; Tamberi S; Cadioli A; Luppi F; Migaldi M; Rossi G
Am J Clin Pathol; 2009 Apr; 131(4):478-89. PubMed ID: 19289583
[TBL] [Abstract][Full Text] [Related]
27. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor mutations in small cell lung cancer.
Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of specific KRAS mutations in lung adenocarcinomas.
Siegfried JM; Gillespie AT; Mera R; Casey TJ; Keohavong P; Testa JR; Hunt JD
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):841-7. PubMed ID: 9332768
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical screening and fluorescence in situ hybridization confirmation of ALK translocation in lung adenocarcinoma and its clinicopathological significance: a single-center large-scale investigation of Chinese patients.
Wang WY; Liang DN; Yao WQ; Wu WL; Li JN; Chen M; Liao DY; Zhang M; Li GD
Hum Pathol; 2014 Jul; 45(7):1414-22. PubMed ID: 24775606
[TBL] [Abstract][Full Text] [Related]
31. Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.
Benesova L; Minarik M; Jancarikova D; Belsanova B; Pesek M
Anticancer Res; 2010 May; 30(5):1667-71. PubMed ID: 20592359
[TBL] [Abstract][Full Text] [Related]
32. Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas.
Rossi G; Cavazza A; Righi L; Sartori G; Bisagni A; Longo L; Pelosi G; Papotti M
Int J Surg Pathol; 2014 Aug; 22(5):401-7. PubMed ID: 24651909
[TBL] [Abstract][Full Text] [Related]
33. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
Angulo B; Suarez-Gauthier A; Lopez-Rios F; Medina PP; Conde E; Tang M; Soler G; Lopez-Encuentra A; Cigudosa JC; Sanchez-Cespedes M
J Pathol; 2008 Feb; 214(3):347-56. PubMed ID: 17992665
[TBL] [Abstract][Full Text] [Related]
34. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung.
Yoshida Y; Shibata T; Kokubu A; Tsuta K; Matsuno Y; Kanai Y; Asamura H; Tsuchiya R; Hirohashi S
Lung Cancer; 2005 Oct; 50(1):1-8. PubMed ID: 15950315
[TBL] [Abstract][Full Text] [Related]
35. The impact of intracytoplasmic mucin in lung adenocarcinoma with pneumonic radiological presentation.
Duruisseaux M; Antoine M; Rabbe N; Poulot V; Fleury-Feith J; Vieira T; Lavolé A; Cadranel J; Wislez M
Lung Cancer; 2014 Mar; 83(3):334-40. PubMed ID: 24461303
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis.
Cao Y; Zhu W; Chen W; Wu J; Hou G; Li Y
Dis Markers; 2019; 2019():5451290. PubMed ID: 31093306
[TBL] [Abstract][Full Text] [Related]
37. Detection of ALK fusion in lung cancer using fluorescence in situ hybridization.
Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Kikuchi R; Date H
Asian Cardiovasc Thorac Ann; 2012 Aug; 20(4):426-31. PubMed ID: 22879549
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia.
Brcic L; Jakopovic M; Misic M; Seiwerth F; Kern I; Smojver-Jezek S; Quehenberger F; Samarzija M; Seiwerth S
Diagn Pathol; 2016 Sep; 11(1):90. PubMed ID: 27655296
[TBL] [Abstract][Full Text] [Related]
39. Molecular Testing in Multiple Synchronous Lung Adenocarcinomas: Case Report and Literature Review.
Rafael OC; Lazzaro R; Hasanovic A
Int J Surg Pathol; 2016 Feb; 24(1):43-6. PubMed ID: 26350052
[TBL] [Abstract][Full Text] [Related]
40. Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers.
Ahn JW; Kim HS; Yoon JK; Jang H; Han SM; Eun S; Shim HS; Kim HJ; Kim DJ; Lee JG; Lee CY; Bae MK; Chung KY; Jung JY; Kim EY; Kim SK; Chang J; Kim HR; Kim JH; Lee MG; Cho BC; Lee JH; Bang D
Genome Med; 2014; 6(2):18. PubMed ID: 24576404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
